Winter cod liver oil 5 mL/day in adults not taking daily vitamin D supplements,
does it really help with Reduced COVID-19, serious COVID-19, and other acute respiratory infections?
research showsGrade D. All four co-primary endpoints were null in a quadruple-blinded trial of 34,601 adults. This is not uncertainty from a poor study: a large trial with 0.05% missingness in key variables tested the claim rigorously and found no benefit.
ads claimCod liver oil 5 mL supplied vitamin D 10 µg and about 1 g of n-3 fatty acids. A null result for this combination cannot be generalized to deficiency treatment or high-dose single ingredients.
Useful facts when choosing a product
- Cod liver oil 5 mL/day supplied vitamin D 10 µg and about 1 g n-3 fatty acids.
- Median exposure was 164 days.
- Registration was prospective: posted 30 October 2020 before the 10 November start.
What the research actually shows
The Norwegian trial randomized 34,601 adults to cod liver oil, 17,278, or flavor-matched corn-oil placebo, 17,323, for a median 164 days. Möller's Tran manufacturer Orkla Health AS funded the work and supplied both cod liver oil and placebo; Oslo University Hospital and the University of Oslo also supported it. The manufacturer reported a null result for its own product. KBH disclosed outside relationships with Olympic Seafood, Amgen, and Sanofi; SMU with Olympic Seafood; AS and KTK were employees of diagnostics company Age Laboratories AS.
Axis 6 B0 evidence ① Allocation concealment: "Randomisation was performed by the Department of Research Support at Oslo University Hospital without involvement of the investigators." ② Masking: "Participants, investigators, care providers, data collectors, outcome assessors, and data analysts were masked to group assignment." ③ Analysis population and missing data: "All randomised participants were included in the intention-to-treat analyses." Missingness in key variables was 0.05%. ④ Prespecified primary endpoint: "Four co-primary endpoints were predefined" — matches NCT04609423
Why this is classified as D (34)
All four co-primary endpoints were null in a 34,601-person quadruple-blinded, prospectively registered intention-to-treat trial, giving D with 34 points.
Counterpoint. Manufacturer funding limits independence, while the manufacturer nevertheless reported a null result for its own product.
Rejudgment record. Cross-check applied — All four co-primary endpoints were null in a 34,601-person quadruple-blinded prospectively registered trial
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced PCR-confirmed SARS-CoV-2 infection | D | Null, RR 1.00 (0.82 to 1.22). |
| Reduced serious COVID-19 | D | Null, RR 1.20 (0.87 to 1.65). |
| Reduced other acute respiratory infections | D | Both indicators were null. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Quadruple-blinded randomized placebo-controlled trial | 17,323 | Orkla Health AS funding and supply of study product and placebo; support from Oslo University Hospital and University of Oslo | Four co-primary endpoints: PCR infection, serious COVID-19, negative test, and self-reported acute respiratory infection | 227 vs 228, RR 1.00 (0.82 to 1.22); 121 vs 101, RR 1.20 (0.87 to 1.65); 8,546 vs 8,565, RR 1.00 (0.97 to 1.04); 3,964 vs 3,834, RR 1.04 (0.97 to 1.11) | Large pivotal quadruple-blinded trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Cod Liver Oil for Winter COVID-19 and Acute Respiratory Infections — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/cod-liver-oil-winter-covid-respiratory-infections/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.